These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 16613687

  • 21. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group.
    Cancer; 2006 Sep 01; 107(5):1014-22. PubMed ID: 16878325
    [Abstract] [Full Text] [Related]

  • 22. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA.
    J Clin Oncol; 2005 Mar 01; 23(7):1500-6. PubMed ID: 15632411
    [Abstract] [Full Text] [Related]

  • 23. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL, Huang HQ, Lin XB, Xia ZJ, Li YH, Wang W, He YJ, Pan ZH, Jiang WQ, Guan ZZ.
    Ai Zheng; 2004 Aug 01; 23(8):943-6. PubMed ID: 15301720
    [Abstract] [Full Text] [Related]

  • 24. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ.
    J Clin Oncol; 2004 Dec 01; 22(23):4711-6. PubMed ID: 15483015
    [Abstract] [Full Text] [Related]

  • 25. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
    Niitsu N, Hayama M, Okamoto M, Khori M, Higashihara M, Tamaru J, Hirano M.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4077-82. PubMed ID: 15217942
    [Abstract] [Full Text] [Related]

  • 26. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J.
    Cancer; 2008 Nov 15; 113(10):2734-41. PubMed ID: 18973182
    [Abstract] [Full Text] [Related]

  • 27. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S, Dührsen U, Nückel H.
    Ann Hematol; 2007 Apr 15; 86(4):271-6. PubMed ID: 17216473
    [Abstract] [Full Text] [Related]

  • 28. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
    Huang HQ, Lin XB, Pan ZH, Bu Q, Gao Y, Wang BF, Cai QQ, Xia ZJ, Xu RH, Jiang WQ, Guan ZZ.
    Zhonghua Zhong Liu Za Zhi; 2007 May 15; 29(5):391-5. PubMed ID: 17892140
    [Abstract] [Full Text] [Related]

  • 29. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
    Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ.
    Cancer J; 2000 May 15; 6(3):146-50. PubMed ID: 10882329
    [Abstract] [Full Text] [Related]

  • 30. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL.
    Oncologist; 2005 Feb 15; 10(2):150-9. PubMed ID: 15709217
    [Abstract] [Full Text] [Related]

  • 31. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D.
    J Clin Oncol; 2006 Sep 01; 24(25):4123-8. PubMed ID: 16896005
    [Abstract] [Full Text] [Related]

  • 32. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P.
    J Clin Oncol; 2003 Jun 01; 21(11):2115-22. PubMed ID: 12775737
    [Abstract] [Full Text] [Related]

  • 33. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N, LaRocca RV, Bard V, Sethuraman G, Foon KA.
    Am J Hematol; 2002 Jul 01; 70(3):181-5. PubMed ID: 12111762
    [Abstract] [Full Text] [Related]

  • 34. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M.
    J Clin Oncol; 2004 Jul 01; 22(13):2654-61. PubMed ID: 15159414
    [Abstract] [Full Text] [Related]

  • 35. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
    Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD.
    J Clin Oncol; 2008 Sep 20; 26(27):4473-9. PubMed ID: 18626004
    [Abstract] [Full Text] [Related]

  • 36. [Primary breast lymphoma--a report of 27 cases with literature review].
    Cao YB, Wang SS, Huang HQ, Xu GC, He YJ, Guan ZZ, Lin TY.
    Ai Zheng; 2007 Jan 20; 26(1):84-9. PubMed ID: 17222374
    [Abstract] [Full Text] [Related]

  • 37. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.
    Ai Zheng; 2006 Dec 20; 25(12):1543-9. PubMed ID: 17166383
    [Abstract] [Full Text] [Related]

  • 38. [MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
    Fan Y, Huang ZY, Luo LH, Yu HF.
    Ai Zheng; 2005 Dec 20; 24(12):1503-6. PubMed ID: 16351801
    [Abstract] [Full Text] [Related]

  • 39. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Luminari S, Marcheselli L, Sacchi S, Pozzi S, Bari A, Ilariucci F, Stelitano C, Angrilli F, Lazzaro A, Baldini L.
    Cancer; 2009 May 01; 115(9):1906-13. PubMed ID: 19248044
    [Abstract] [Full Text] [Related]

  • 40. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
    Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, Troiani E, Scortechini I, Poloni A, Leoni P.
    Biol Blood Marrow Transplant; 2005 Aug 01; 11(8):627-36. PubMed ID: 16041313
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.